Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
US employers may halt GLP-1 drug coverage in 2027 amid rising costs and usage spikes
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Reports highlighted growing employer concerns over rising demand and cost, but no resolutions or policy changes were confirmed. The trend faded without a definitive conclusion in the coverage.
Epilogue added 157d ago, after coverage quieted.
The brief
A growing number of US employers are preparing to exclude GLP-1 weight-loss medications—such as Ozempic and Wegovy—from health plans starting next year. Coverage from *Forbes*, *The Wall Street Journal*, and *Reuters* highlights concerns over escalating prescription demand, which has outpaced budget projections. Some state-level discussions, including California’s consideration for public employees, signal broader policy shifts ahead.
Business and healthcare outlets—including *Modern Healthcare*, *Fierce Healthcare*, and *Yahoo Finance*—emphasize the financial strain on pharmacy benefit managers (PBMs) and corporate insurers. Reports note that employers are reassessing pharmacy benefits, with some exploring tiered coverage or outright exclusions. Analysts cited in *Fierce Healthcare* suggest payers may adopt stricter criteria for GLP-1 prescriptions, though no uniform policy has been announced.
Watch for potential legal challenges from patients or advocacy groups if exclusions proceed. Pharmaceutical manufacturers may respond with pricing adjustments or alternative reimbursement models, though no such moves have been reported yet.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (89% supported) Updated 158d ago.
Quick answers
Which GLP-1 drugs are most affected by potential coverage drops?
Coverage emphasizes Ozempic (semaglutide) and Wegovy (tirzepatide) as the primary GLP-1 medications under review by employers.
Are any states already restricting GLP-1 coverage?
California is actively debating whether to cover Ozempic for public employees, but no final decisions have been made.
Will patients lose access to these drugs if employers drop coverage?
Coverage does not yet specify how patients would be impacted, but exclusions could force them to pay out-of-pocket or seek alternative treatments.
Coverage (8)
- Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying Forbes · 159d ago
- Some employers are dropping weight loss drug coverage as use surges qz.com · 159d ago
- Your Weight-Loss Drugs Are Next on the Corporate Chopping Block WSJ · 159d ago
- Can California afford to cover Ozempic for public employees? CalMatters · 159d ago
- U.S. employers dropping GLP-1 weight loss drug coverage in 2027 Yahoo Finance · 159d ago
- Employers are rethinking pharmacy benefits: 5 things to know Modern Healthcare · 159d ago
- PSG report examines payers and employers’ attitudes towards GLP-1 coverage, unbundling’ PBM models Fierce Healthcare · 159d ago
- Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases Reuters · 159d ago
Topics
Related trends
Ozempic and Mounjaro may have a surprising effect on your brain
Coverage from five outlets reports that Ozempic and Mounjaro may affect memory and brain function, with evidence described as mixed.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.